|
시장보고서
상품코드
2077522
연골 무형성증 치료 시장 : 치료 유형별, 투여 경로별, 유통 채널별, 지역별Achondroplasia Treatment Market, By Treatment Type, By Route of Administration, By Distribution Channel, by Region |
||||||
연골 무형성증 치료 시장은 2026년에 3억 2,600만 달러 규모가 될 것으로 추정되고 있어 2033년에 29억 830만 달러에 이를 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 36.7%로 성장할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 3억 2,600만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년까지 예측 기간 CAGR : | 36.70% | 2033년 시장 규모 예측 : | 29억 830만 달러 |
연골 무형성증은 사지가 짧은 왜소증의 일종입니다. 연골 무형성증은 평균적인 크기의 몸통, 짧은 팔과 다리(특히 상완과 대퇴부가 현저히 짧음), 팔꿈치 관절의 가동 범위 제한, 머리의 비대 등을 특징으로 합니다. 척추관 협착증은 척추관이 좁아져 척수 상부를 압박할 가능성이 있는 질환으로, 연골 무형성증의 잠재적으로 심각한 합병증 중 하나입니다. 척추관 협착증은 다리의 통증, 저림, 근력 저하를 특징으로 하며, 보행 곤란을 유발할 수 있습니다. 연골 무형성증은 FGFR3 유전자의 변이로 인해 발생합니다. FGFR3 유전자는 뼈와 뇌 조직의 발달 및 유지에 관여하는 단백질을 합성할 때 필요한 지침을 제공하는 역할을 합니다.
시장 역학
규제 당국의 연골 무형성증 치료제 승인 건수 증가가 예측 기간 동안 시장 성장을 견인할 것으로 예측됩니다. 예를 들어, 2021년 11월, 세계적인 생명공학 기업인 바이오마린(BioMarin)은 미국 식품의약국(FDA)이 골단선(성장판)이 열려 있는 5세 이상의 연골 무형성증 소아 환자의 직선 성장 촉진을 적응증으로 하는 주사제 'VOXZOGO(보솔리티드)'에 대해 신속 승인을 부여했다고 발표했습니다. 또한, 2021년 8월에는 BridgeBio Pharma, Inc.의 자회사인 QED Therapeutics가 2세부터 성장판이 닫힐 때까지(사춘기를 거쳐 최종 성인 키에 도달한 시점)의 소아 연골 무형성증 치료제로, 1일 1회 주사제 ' VOXZOGO(보솔리티드)'에 대해 유럽위원회(EC)로부터 판매 승인을 받았다고 발표했습니다.
또한, 연골 무형성증 치료에 활용된 주요 기업들의 연구 개발이 활발해짐에 따라, 예측 기간 동안 치료 부문의 성장을 견인할 것으로 전망됩니다. 예를 들어, 2021년 11월, 아프타마 치료 전문 임상 단계 제약 기업인 RIBOMIC, Inc.는 연골 무형성증 치료를 목적으로 한 RBM-007을 사용한 1상 임상시험(건강한 지원자 대상) 결과를 발표했습니다. 해당 검사는 2021년 5월에 완료되었습니다.
본 검사의 주요 특징:
- 본 조사는 다양한 부문에 걸친 잠재적 수익 기회를 밝혀내고, 이 시장에서 매력적인 투자 제안 매트릭스를 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
- 본 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 연골 무형성증 치료 시장의 주요 기업 프로파일을 발표하고 있습니다.
- 본 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있게 됩니다.
- 본 '세계 연골 무형성증 치료 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 아콘드로플라지아 치료 시장 분석에 사용된 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있습니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 연골 무형성증치료 시장,
제5장 세계의 연골 무형성증치료 시장 : 치료 유형별, 2021-2033년
제6장 세계의 연골 무형성증치료 시장 : 투여 경로별, 2021-2033년
제7장 세계의 연골 무형성증치료 시장 : 유통 채널별, 2021-2033년
제8장 세계의 연골 무형성증치료 시장 : 지역별, 2021-2033년
제9장 경쟁 구도
제10장 섹션
JHS 26.07.13Achondroplasia Treatment Market is estimated to be valued at USD 326.0 Mn in 2026 and is expected to reach USD 2,908.3 Mn by 2033, growing at a compound annual growth rate (CAGR) of 36.7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 326.0 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 36.70% | 2033 Value Projection: | USD 2,908.3 Mn |
Achondroplasia is a form of short-limbed dwarfism. Achondroplasia is characterized by an average-sized trunk, short arms and legs, notably short upper arms and thighs, a limited range of motion at the elbows, and an enlarged head. Spinal stenosis, a narrowing of the spinal canal that can compress the upper section of the spinal cord, is a potentially serious complication of achondroplasia. Spinal stenosis is characterized by leg pain, tingling, and weakness, which can make walking difficult. Achondroplasia is caused by mutations in the FGFR3 gene. The FGFR3 gene is responsible for giving instructions when making a protein that is involved in the development and maintenance of bone and brain tissue.
Market Dynamics
Increasing approvals of achondroplasia treatment drugs by regulatory bodies are expected to drive the market growth over the forecast period. For instance, in November 2021, BioMarin, a global biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had granted accelerated approval to VOXZOGO (vosoritide) for injection, indicated to increase linear growth in pediatric patients with achondroplasia of five years of age and older with open epiphyses (growth plates). Moreover, in August 2021, QED Therapeutics, a subsidiary of BridgeBio Pharma, Inc., announced that the European Commission (EC) had granted marketing authorization for VOXZOGO (vosoritide), a once-daily injection to treat achondroplasia in children from the age of 2 until growth plates are closed, which occurs after puberty when children reach final adult height.
Also, increasing research and development by key players for the treatment of achondroplasia is expected to drive the treatment segment growth over the forecast period. For instance, in November 2021, RIBOMIC, Inc., a clinical stage pharmaceutical company specialized in aptamer therapeutics, announced the results from its Phase 1, healthy volunteer clinical study using RBM-007 for the planned treatment of achondroplasia, which was completed in May 2021.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global Achondroplasia Treatment market based on the following parameters- Company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include BioMarin, RIBOMIC, Ascendis Pharma A/S, BridgeBio Pharma, Inc., Pfizer Inc., PhaseBio Pharmaceuticals, Inc., SiSaf, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, LG Chem, Ferring B.V., JCR Pharmaceuticals Co., Ltd, KVK TECH, INC., VIVUS LLC., ProLynx Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Ipsen Pharma, Novartis AG, and Xiamen Amoytop Biotech Co., Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global achondroplasia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global achondroplasia treatment market.
Detailed Segmentation:
- Global Achondroplasia Treatment Market, By Treatment Type (Revenue, USD Mn, 2021 - 2033)
- Vosoritide
- Human Growth Hormone
- Others
- Global Achondroplasia Treatment Market, By Route of Administration:
- Oral
- Parenteral
- Global Achondroplasia Treatment Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Achondroplasia Treatment, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- BioMarin
- RIBOMIC
- Ascendis Pharma A/S
- BridgeBio Pharma, Inc.
- Pfizer Inc.
- PhaseBio Pharmaceuticals, Inc.
- SiSaf
- Novo Nordisk A/S
- Hoffmann-La Roche Ltd
- LG Chem
- Ferring B.V.
- JCR Pharmaceuticals Co., Ltd
- KVK TECH, INC.
- VIVUS LLC.
- ProLynx Inc.
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- Ipsen Pharma
- Novartis AG
- Xiamen Amoytop Biotech Co., Ltd.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Treatment Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Drug Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Achondroplasia Treatment Market,
- Economic Impact
- Impact on Supply and Demand
5. Global Achondroplasia Treatment Market, By Treatment Type, 2021 €" 2033 (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- Vosoritide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Human Growth Hormone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
6. Global Achondroplasia Treatment Market, By Route of Administration, 2021 €" 2033 (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
7. Global Achondroplasia Treatment Market, By Distribution Channel, 2021 €" 2033 (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
8. Global Achondroplasia Treatment Market, By Regions, 2021 €" 2033 (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Country, 2021 €" 2033, (US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Country, 2021 €" 2033, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Country, 2021 €" 2033, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Country, 2021 €" 2033, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Country, 2021 €" 2033, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Country, 2021 €" 2033, (US$ Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- BioMarin
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- RIBOMIC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ascendis Pharma A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- BridgeBio Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- PhaseBio Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- SiSaf
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novo Nordisk A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- F.Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- LG Chem
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ferring B.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- JCR Pharmaceuticals Co., Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- KVK TECH, INC.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- VIVUS LLC.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- ProLynx Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ipsen Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Xiamen Amoytop Biotech Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- BioMarin
10. Section
- References
- Research Methodology
- About us and Sales Contact
